METHOD FOR PREDICTION OF ENDOMETRIAL HYPERPLASIA IN PATIENTS WITH HYSTEROMYOMA FOLLOWING UTERINE ARTERY EMBOLISATION Russian patent published in 2015 - IPC G01N33/53 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to gynaecology, and concerns a method for the prediction of endometrial hyperplasia in the patients with hysteromyoma following uterine artery embolisation (UAE). Substance of the method: all the patients undergo a pre-UEA diagnostic and therapeutic uterine scrapping; 6 months after the UAE, an endometrial pipelle biopsy followed by a pathomorphological study of the biopsy material is conducted. If the study shows no pathology, the biopsy materials are analysed by means of an immune histochemical study using anti-Ki-67 monoclononal antibodies; a percentage of Ki-67 proliferation marker in the uterine gland epithelium (coefficient A) and in the endometrial stroma (coefficient B) is determined; a prognostic index D₁ is calculated in initial(pre-UEA) non-atypical hyperplasia, and a prognostic index D₂ - in initial (pre-UEA) endometrium in the late proliferation phase: D₁=A*0.05-0.74 and D₂=B*0.02-0.3. If D₁ is 0 or more, recurrent endometrial hyperplasia is predicted, whereas D₁ less than 0 enables stating a low risk of recurrent endometrial hyperplasia. If D₂ is more than 0, a low risk of developing endometrial hyperplasia is stated, whereas D₂ of 0 or less shows developing endometrial hyperplasia.

EFFECT: presented method enables the high-accuracy prediction of the post-UEA endometrial hyperplasia that makes it possible to prescribe the preventive hormone therapy in due time.

4 ex